Cargando…
High expression of TRF2, SOX10, and CD10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressiveness
Circulating tumors cells (CTCs) can be detected in the blood of metastatic melanoma patients (MMPs) both as isolated circulating tumor cells (iCTCs) and circulating tumor microemboli (CTMs), but their clinical significance remains unknown. The aim of this work was to evaluate the prognostic impact i...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924359/ https://www.ncbi.nlm.nih.gov/pubmed/26945789 http://dx.doi.org/10.1002/cam4.661 |
_version_ | 1782439858261721088 |
---|---|
author | Long, Elodie Ilie, Marius Bence, Coraline Butori, Catherine Selva, Eric Lalvée, Salomé Bonnetaud, Christelle Poissonnet, Gilles Lacour, Jean‐Philippe Bahadoran, Philippe Brest, Patrick Gilson, Eric Ballotti, Robert Hofman, Véronique Hofman, Paul |
author_facet | Long, Elodie Ilie, Marius Bence, Coraline Butori, Catherine Selva, Eric Lalvée, Salomé Bonnetaud, Christelle Poissonnet, Gilles Lacour, Jean‐Philippe Bahadoran, Philippe Brest, Patrick Gilson, Eric Ballotti, Robert Hofman, Véronique Hofman, Paul |
author_sort | Long, Elodie |
collection | PubMed |
description | Circulating tumors cells (CTCs) can be detected in the blood of metastatic melanoma patients (MMPs) both as isolated circulating tumor cells (iCTCs) and circulating tumor microemboli (CTMs), but their clinical significance remains unknown. The aim of this work was to evaluate the prognostic impact in metastatic cutaneous melanoma of CTMs and iCTCs identified by a cytomorphological approach using the isolation by size of tumor cell (ISET) method. We characterized the phenotype of CTCs using anti‐PS100, anti‐SOX10, anti‐CD10, and anti‐TRF2 antibodies. 128 MMPs and 37 control healthy individuals with benign nevi were included in this study. Results were compared to the follow‐up of patients. 109/128 (85%) MMPs showed CTCs, 44/128 (34%) with 2 to 6 CTMs and 65/128 (51%) with 4 to 9 iCTCs. PS100 expression was homogeneous in iCTCs and heterogeneous in CTMs. SOX10, CD10, and TRF2 were mainly expressed in CTMs. None of the control subjects demonstrated circulating malignant tumor cells. Overall survival was significantly decreased in patients with CTMs, independently of the therapeutic strategies. In conclusion, the presence of CTMs is an independent predictor of shorter survival from the time of diagnosis of MMPs. |
format | Online Article Text |
id | pubmed-4924359 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-49243592016-06-29 High expression of TRF2, SOX10, and CD10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressiveness Long, Elodie Ilie, Marius Bence, Coraline Butori, Catherine Selva, Eric Lalvée, Salomé Bonnetaud, Christelle Poissonnet, Gilles Lacour, Jean‐Philippe Bahadoran, Philippe Brest, Patrick Gilson, Eric Ballotti, Robert Hofman, Véronique Hofman, Paul Cancer Med Clinical Cancer Research Circulating tumors cells (CTCs) can be detected in the blood of metastatic melanoma patients (MMPs) both as isolated circulating tumor cells (iCTCs) and circulating tumor microemboli (CTMs), but their clinical significance remains unknown. The aim of this work was to evaluate the prognostic impact in metastatic cutaneous melanoma of CTMs and iCTCs identified by a cytomorphological approach using the isolation by size of tumor cell (ISET) method. We characterized the phenotype of CTCs using anti‐PS100, anti‐SOX10, anti‐CD10, and anti‐TRF2 antibodies. 128 MMPs and 37 control healthy individuals with benign nevi were included in this study. Results were compared to the follow‐up of patients. 109/128 (85%) MMPs showed CTCs, 44/128 (34%) with 2 to 6 CTMs and 65/128 (51%) with 4 to 9 iCTCs. PS100 expression was homogeneous in iCTCs and heterogeneous in CTMs. SOX10, CD10, and TRF2 were mainly expressed in CTMs. None of the control subjects demonstrated circulating malignant tumor cells. Overall survival was significantly decreased in patients with CTMs, independently of the therapeutic strategies. In conclusion, the presence of CTMs is an independent predictor of shorter survival from the time of diagnosis of MMPs. John Wiley and Sons Inc. 2016-03-06 /pmc/articles/PMC4924359/ /pubmed/26945789 http://dx.doi.org/10.1002/cam4.661 Text en © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Long, Elodie Ilie, Marius Bence, Coraline Butori, Catherine Selva, Eric Lalvée, Salomé Bonnetaud, Christelle Poissonnet, Gilles Lacour, Jean‐Philippe Bahadoran, Philippe Brest, Patrick Gilson, Eric Ballotti, Robert Hofman, Véronique Hofman, Paul High expression of TRF2, SOX10, and CD10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressiveness |
title | High expression of TRF2, SOX10, and CD10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressiveness |
title_full | High expression of TRF2, SOX10, and CD10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressiveness |
title_fullStr | High expression of TRF2, SOX10, and CD10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressiveness |
title_full_unstemmed | High expression of TRF2, SOX10, and CD10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressiveness |
title_short | High expression of TRF2, SOX10, and CD10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressiveness |
title_sort | high expression of trf2, sox10, and cd10 in circulating tumor microemboli detected in metastatic melanoma patients. a potential impact for the assessment of disease aggressiveness |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924359/ https://www.ncbi.nlm.nih.gov/pubmed/26945789 http://dx.doi.org/10.1002/cam4.661 |
work_keys_str_mv | AT longelodie highexpressionoftrf2sox10andcd10incirculatingtumormicroembolidetectedinmetastaticmelanomapatientsapotentialimpactfortheassessmentofdiseaseaggressiveness AT iliemarius highexpressionoftrf2sox10andcd10incirculatingtumormicroembolidetectedinmetastaticmelanomapatientsapotentialimpactfortheassessmentofdiseaseaggressiveness AT bencecoraline highexpressionoftrf2sox10andcd10incirculatingtumormicroembolidetectedinmetastaticmelanomapatientsapotentialimpactfortheassessmentofdiseaseaggressiveness AT butoricatherine highexpressionoftrf2sox10andcd10incirculatingtumormicroembolidetectedinmetastaticmelanomapatientsapotentialimpactfortheassessmentofdiseaseaggressiveness AT selvaeric highexpressionoftrf2sox10andcd10incirculatingtumormicroembolidetectedinmetastaticmelanomapatientsapotentialimpactfortheassessmentofdiseaseaggressiveness AT lalveesalome highexpressionoftrf2sox10andcd10incirculatingtumormicroembolidetectedinmetastaticmelanomapatientsapotentialimpactfortheassessmentofdiseaseaggressiveness AT bonnetaudchristelle highexpressionoftrf2sox10andcd10incirculatingtumormicroembolidetectedinmetastaticmelanomapatientsapotentialimpactfortheassessmentofdiseaseaggressiveness AT poissonnetgilles highexpressionoftrf2sox10andcd10incirculatingtumormicroembolidetectedinmetastaticmelanomapatientsapotentialimpactfortheassessmentofdiseaseaggressiveness AT lacourjeanphilippe highexpressionoftrf2sox10andcd10incirculatingtumormicroembolidetectedinmetastaticmelanomapatientsapotentialimpactfortheassessmentofdiseaseaggressiveness AT bahadoranphilippe highexpressionoftrf2sox10andcd10incirculatingtumormicroembolidetectedinmetastaticmelanomapatientsapotentialimpactfortheassessmentofdiseaseaggressiveness AT brestpatrick highexpressionoftrf2sox10andcd10incirculatingtumormicroembolidetectedinmetastaticmelanomapatientsapotentialimpactfortheassessmentofdiseaseaggressiveness AT gilsoneric highexpressionoftrf2sox10andcd10incirculatingtumormicroembolidetectedinmetastaticmelanomapatientsapotentialimpactfortheassessmentofdiseaseaggressiveness AT ballottirobert highexpressionoftrf2sox10andcd10incirculatingtumormicroembolidetectedinmetastaticmelanomapatientsapotentialimpactfortheassessmentofdiseaseaggressiveness AT hofmanveronique highexpressionoftrf2sox10andcd10incirculatingtumormicroembolidetectedinmetastaticmelanomapatientsapotentialimpactfortheassessmentofdiseaseaggressiveness AT hofmanpaul highexpressionoftrf2sox10andcd10incirculatingtumormicroembolidetectedinmetastaticmelanomapatientsapotentialimpactfortheassessmentofdiseaseaggressiveness |